GC Green Cross Wellbeing launches intra-articular injection 'Conrod'

The First Korean Clinical Trial for Domestic Intra-Articular Injection Agent

GC Green Cross Wellbeing launches intra-articular injection 'Conrod'.

[Asia Economy Reporter Lee Gwan-ju] GC Green Cross Wellbeing is introducing the first intra-articular injection in Korea to undergo clinical trials on Korean patients.

On the 13th, GC Green Cross Wellbeing announced the launch of ‘Conrod,’ an intra-articular injection for patients with degenerative arthritis. Unlike existing products that were clinically tested on Europeans, this product secured safety and efficacy through clinical trials conducted on Koreans.

‘Conrod’ is an intra-articular injection whose main ingredient is polynucleotide sodium (PN) extracted from the DNA of salmonid fish. It has a gel form with high viscosity and elasticity, which reduces physical friction in the joints and helps improve knee pain. It has also obtained the European Community Mark (CE), certifying its suitability for entry into the European market.

The manufacturer, BR Pharm, enhanced product quality through domestic eco-friendly sea trout farming and traceability management, and ensured safety by extracting high-purity PN using a patented manufacturing process. Both raw materials and finished products are produced in-house at a GMP-certified domestic production facility.

A GC Green Cross Wellbeing official stated, “With the increase in patients with degenerative arthritis, the domestic intra-articular treatment market is rapidly growing,” adding, “‘Conrod’ is a product proven for excellence and safety, and we expect it to quickly capture the intra-articular treatment market.”

This content was produced with the assistance of AI translation services.